GlassScriptPhysician profile
Dain E Wahl
NPI 1750336897
$4,957.51
in general payments reported to CMS, 2019-2025
25 companies · $1,179 in 2025
The $1,179 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.23 · 2020: $160 · 2021: $694 · 2022: $794 · 2023: $844 · 2024: $1,255 · 2025: $1,179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,266 · Education: $12.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,265.51 |
| Education | $12.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,033.01 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $613.16 | 2020-2025 | Mounjaro, Zepbound, Emgality |
| Novo Nordisk INC | $563.47 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Gilead Sciences, INC. | $257.60 | 2021-2025 | |
| Antares Pharma, INC. | $222.54 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Astrazeneca Pharmaceuticals LP | $178.61 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Otsuka America Pharmaceutical, INC. | $160.87 | 2024-2025 | Rexulti |
| Axsome Therapeutics, INC. | $125.07 | 2023-2024 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $100.46 | 2025 | Caplyta |
| Amgen INC. | $87.65 | 2021-2022 | |
| Abbott Laboratories | $83.45 | 2021-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $77.28 | 2024-2025 | Veozah |
| Pfizer INC. | $72.01 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $60.38 | 2022 | |
| Hologic Sales and Service, LLC | $52.85 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $45.17 | 2022-2024 | Apretude |
| Allergan, INC. | $38.01 | 2020 | |
| Biogen, INC. | $34.40 | 2021 | |
| Halozyme INC | $32.86 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.58 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $29.20 | 2024-2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $16.00 | 2021 | |
| Vanda Pharmaceuticals INC. | $15.00 | 2024 | Hetlioz, Fanapt |
| Exact Sciences Corporation | $14.69 | 2025 | Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $14.19 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dain Wahl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.